These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3957489)

  • 1. Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
    Piotrovskii VK; Rumiantsev DO; Nikolenko SA; Riabokon OS; Metelitsa VI
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):4-11. PubMed ID: 3957489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
    Tartaglione TA; Pieper JA; Lopez LL; Mehta J
    Res Commun Chem Pathol Pharmacol; 1983 Apr; 40(1):15-27. PubMed ID: 6867470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration.
    Asthana OP; Woodcock BG; Wenchel M; Frömming KH; Schwabe L; Rietbrock N
    Arzneimittelforschung; 1984; 34(4):498-502. PubMed ID: 6540109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy].
    Rumiantsev DO; Piotrovskiĭ VK; Metelitsa VI; Riabokon' OS; Kokurina EV
    Farmakol Toksikol; 1988; 51(1):66-70. PubMed ID: 3360112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration].
    Woodcock BG; Wörner P; Rietbrock N; Schwabe L; Frömming KH
    Arzneimittelforschung; 1982; 32(12):1567-71. PubMed ID: 6891597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
    Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of verapamil in man.
    Koike Y; Shimamura K; Shudo I; Saito H
    Res Commun Chem Pathol Pharmacol; 1979 Apr; 24(1):37-47. PubMed ID: 432439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
    Kim HJ; Choi JS
    Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of oral verapamil therapy on antipyrine clearance.
    Rumiantsev DO; Piotrovskii VK; Riabokon OS; Slastnikova ID; Kokurina EV; Metelitsa VI
    Br J Clin Pharmacol; 1986 Nov; 22(5):606-9. PubMed ID: 3790408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
    Piao YJ; Choi JS
    Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism.
    Tannergren C; Engman H; Knutson L; Hedeland M; Bondesson U; Lennernäs H
    Clin Pharmacol Ther; 2004 Apr; 75(4):298-309. PubMed ID: 15060508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of calcium channel blocking agents.
    Anderson P
    Acta Pharmacol Toxicol (Copenh); 1986; 58 Suppl 2():43-57. PubMed ID: 2940799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
    Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
    Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
    Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy.
    Vlcek J; Macek K; Hůlek P; Brátová M; Fendrich Z
    Arzneimittelforschung; 1995 Feb; 45(2):146-9. PubMed ID: 7710436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits.
    Choi JS; Han HK
    J Pharm Pharmacol; 2004 Dec; 56(12):1537-42. PubMed ID: 15563760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral and intravenous pharmacokinetics of cimetidine in liver cirrhosis.
    Okolicsanyi L; Venuti M; Orlando R; Lirussi F; Nassuato G; Benvenuti C
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):482-7. PubMed ID: 7141756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration.
    Abernethy DR; Wainer IW; Anacleto AI
    Drug Metab Dispos; 2000 Jul; 28(7):760-5. PubMed ID: 10859149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.